Midazolam buccal - Shire

Drug Profile

Midazolam buccal - Shire

Alternative Names: Buccolam; MHOS; Midazolam hydrochloride oromucosal solution; SHP-615

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therakind; ViroPharma
  • Developer Shire; Therakind
  • Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Epilepsy

Most Recent Events

  • 08 Nov 2017 Shire plans a phase III trial for Epilepsy (In infants, In children, In adolescents) in Japan (NCT03336645)
  • 08 Nov 2017 Shire plans a phase III extension trial for Epilepsy (In infants, In children, In adolescents) in Japan (NCT03336450)
  • 01 Oct 2017 Phase-II clinical trials in Epilepsy in Japan (Buccal) prior to October 2017 (Shire pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top